| Identification | Back Directory | [Name]
NCX899 | [CAS]
690655-41-5 | [Synonyms]
NCX899
L-Proline, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-, 3-(nitrooxy)propyl ester | [Molecular Formula]
C23H33N3O8 | [MDL Number]
MFCD31382168 | [MOL File]
690655-41-5.mol | [Molecular Weight]
479.52 |
| Chemical Properties | Back Directory | [Boiling point ]
622.7±55.0 °C(Predicted) | [density ]
1.229±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
5.43±0.39(Predicted) |
| Hazard Information | Back Directory | [Uses]
NCX899 is a NO-releasing derivative of enalapril, and shows inhibitory activity against angiotensin-converting enzyme (ACE) activity. | [in vivo]
NCX 899 (NCX, 25 mg/kg, n=10) decreases the end-diastolic dimension in cardiomyopathic (CM) with heart failure. NCX 899 inhibits ACE activity and increases the plasma nitrate levels in CM hamster[1]. NCX899 (4 micromol/kg, i.v.) inhibits the activity of serum angiotensin-converting enzyme in dogs. NCX899 significantly attenuates both arterial hypertension and bradycardia[2]. | [References]
[1] Iwanaga Y, et al. A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. FASEB J. 2004 Mar;18(3):587-8. Epub 2004 Jan 20. DOI:10.1096/fj.03-0872fje
[2] Okuyama CE, et al. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. Clin Exp Pharmacol Physiol. 2007 Apr;34(4):290-5. DOI:10.1111/j.1440-1681.2007.04559.x |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|